

Dekel Gelbman, LL.B., MBA

Dekel is the CEO of Nevia Bio, a diagnostic company pioneering a new type of liquid biopsy analysis – vaginal secretions - for early detection of ovarian and other gynecological cancers. He has over 15 years of leadership experience in diagnostics, genomics, and AI-driven healthcare solutions. Prior to Nevia Bio, Dekel was Senior Vice President of Business Development and Partnerships at Day Zero Diagnostics, where he led commercial and strategic initiatives for AI-powered infectious disease diagnostics and helped raise over \$40M in equity and non-dilutive funding. Prior to that, Dekel was the founding CEO of FDNA, a rare disease diagnostic company, using AI and facial analysis software to shorten the diagnostic odyssey of children born with genetic disorders. At FDNA, he spearheaded the development and global adoption of digital health solutions and secured more than \$35M in funding. Earlier in his career, Dekel was a corporate and transactional attorney in leading firms in Israel and in the United States (Skadden, Arps and Naschitz, Brandes, Amir). His expertise spans regulatory strategy, commercialization, and partnerships in the diagnostics space. Dekel holds an MBA from Reichman University and a law degree (LL.B) from Tel Aviv University. Passionate about advancing precision medicine, he is dedicated to bringing breakthrough diagnostic technologies to market and improving patient outcomes.